FOLH1 and prostate cancer: Imaging of prostate cancer both at initial staging and at recurrence has been revolutionized by the advent of positron emission tomography (PET) tracers targeted to prostate specific membrane antigen (PSMA) which have shown superiority in comparison with conventional imaging comprising CT and bone scintigraphy [2–4].